Drug Trial Radar · NCT01144338
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14,752
Actual
Start
Jun 18, 2010
Primary completion
Apr 21, 2017
Study completion Apr 24, 2017
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Exenatide Once WeeklyDrug
Subcutaneous injection, 2 mg, administered once weekly.
PlaceboDrug
Subcutaneous injection, matching volume of placebo, administered once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Outcome MACE EventsTime frame: Time to first event. Information collected during study period (anticipated to be up to 7.5 years).
- Primary Safety Outcome MACE EventsTime frame: Time to first event. Information collected during study period (anticipated to be up to 7.5 years).
Locations
629 sites in 35 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Glendale, Arizona
Research Site
Phoenix, Arizona
Research Site
Jonesboro, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Chula Vista, California
Research Site
Concord, California
Research Site
Escondido, California
Research Site
Fullerton, California
Research Site
Greenbrae, California
Research Site
La Mesa, California
Research Site
Laguna Hills, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Oceanside, California
Research Site
Orange, California
Research Site
Redondo Beach, California
Research Site
San Diego, California
Research Site
San Diego, California
Research Site
Sylmar, California
Research Site
Torrance, California
Research Site
Tustin, California
Research Site
Victorville, California
Research Site
Aurora, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Littleton, Colorado
Research Site
Thomaston, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Cape Coral, Florida
Research Site
Fort Lauderdale, Florida
Research Site
Jacksonville, Florida
Research Site
Sarasota, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Marietta, Georgia
Research Site
Roswell, Georgia
Research Site
Pocatello, Idaho
Research Site
Chicago, Illinois
Showing 40 of 629 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.